Bakhshiani Zahra, Fouladi Saloomeh, Mohammadzadeh Samaneh, Eskandari Nahid
Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Poursina Hakim Digestive Diseases Research Center, Isfahan University of Medical Scineces, Isfahan, Iran.
Cell J. 2021 Apr;23(1):14-20. doi: 10.22074/cellj.2021.6941. Epub 2021 Mar 1.
Sepsis results from dysregulated host responses to infection, and it is a major cause of mortality in the world. Co-inhibitory molecules, such as PD-1, play a critical role in this process. Considering the lack of information on the relation between sPD1 and sepsis, the present study aimed to examine the sPD1 level in septic patients and evaluate its correlation with procalcitonin (PCT) and C-reactive protein (CRP) levels.
This descriptive cross-sectional study consisted of three groups, including septic patients (n=15), suspected of sepsis (n=15), and healthy subjects (n=15). White blood cells (WBCs) and platelet (PLT) counts are evaluated. The serum levels of CRP, PCT, and sPD1 were measured by immunoturbidimetric assay, electrochemiluminescence technology, and the enzyme-linked immunosorbent assay (ELISA), respectively.
Our study indicated that there was a significant difference in WBC and PLT counts between the septic group compared to suspected and control groups (P<0.001, P<0.01, respectively). The CRP level was significantly higher in septic compared to suspected and control groups (P<0.001). There was also a significant difference between the PCT level in septic and suspected groups in comparison with the controls (P<0.001, P<0.01). The sPD1 level was significantly higher in septic patients compared to suspected and control groups (P< 0.001). In septic patients, sPD1 levels were correlated positively with the CRP and PCT levels.
Overall, sPD1 correlation with inflammatory markers, might propose it as a potential biomarker to sepsis diagnosis. However, the clinical application of serum sPD-1 testing in patients with sepsis requires further investigation.
脓毒症源于宿主对感染的反应失调，是全球主要的死亡原因。共抑制分子，如程序性死亡受体1（PD - 1），在此过程中起关键作用。鉴于缺乏可溶性程序性死亡受体1（sPD1）与脓毒症关系的相关信息，本研究旨在检测脓毒症患者的sPD1水平，并评估其与降钙素原（PCT）和C反应蛋白（CRP）水平的相关性。
本描述性横断面研究包括三组，分别为脓毒症患者（n = 15）、疑似脓毒症患者（n = 15）和健康受试者（n = 15）。评估白细胞（WBC）和血小板（PLT）计数。分别采用免疫比浊法、电化学发光技术和酶联免疫吸附测定（ELISA）检测CRP、PCT和sPD1的血清水平。
我们的研究表明，与疑似脓毒症组和对照组相比，脓毒症组的WBC和PLT计数存在显著差异（分别为P < 0.001，P < 0.01）。与疑似脓毒症组和对照组相比，脓毒症组的CRP水平显著更高（P < 0.001）。与对照组相比，脓毒症组和疑似脓毒症组的PCT水平也存在显著差异（P < 0.001，P < 0.01）。与疑似脓毒症组和对照组相比，脓毒症患者的sPD1水平显著更高（P < 0.001）。在脓毒症患者中，sPD1水平与CRP和PCT水平呈正相关。
总体而言，sPD1与炎症标志物的相关性可能使其成为脓毒症诊断的潜在生物标志物。然而，血清sPD - 1检测在脓毒症患者中的临床应用需要进一步研究。
